Naproxen sodium/sumatriptan - Aralez Pharmaceuticals/Pernix Therapeutics Holdings

Drug Profile

Naproxen sodium/sumatriptan - Aralez Pharmaceuticals/Pernix Therapeutics Holdings

Alternative Names: MT-400; Naproxen sodium/sumatriptan succinate; SumaRT/Nap; Sumatriptan/naproxen sodium; Trexima; Treximet

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GlaxoSmithKline; POZEN
  • Developer Aralez Pharmaceuticals Inc.; Pernix Therapeutics Holdings
  • Class Anti-inflammatories; Antimigraines; Indoles; Naphthaleneacetic acids; Non-opioid analgesics; Nonsteroidal anti-inflammatories; Sulfonamides; Tryptamines
  • Mechanism of Action Cyclooxygenase inhibitors; Serotonin 1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Migraine

Most Recent Events

  • 28 Jul 2017 Chemical structure information added
  • 15 Dec 2016 Biomarkers information updated
  • 28 Sep 2016 Launched for Migraine (In adolescents) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top